جدول الترويج Rezolute, Inc.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. مزيد من التفاصيل| EBITDA | -0.0255 |
|---|---|
| Число акций ао | 0.05119 млрд |
| P/BV | 10.04 |
| EV/EBITDA | -0.2369 |
| Цена ао | 2.12 |
| ISIN | US76200L3096 |
| Сайт | https://www.rezolutebio.com |
| Валюта | usd |
| IPO date | 2014-05-01 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| تغير السعر يوميا: | +3.88% (4.9) |
|---|---|
| تغير السعر في الأسبوع: | +2.21% (4.98) |
| تغير السعر شهريا: | +16.48% (4.37) |
| تغير السعر خلال 3 أشهر: | +22.65% (4.15) |
| تغير السعر على مدى ستة أشهر: | +103.6% (2.5) |
| تغير السعر سنويا: | +377.49% (1.066) |
| تغير السعر على مدى 3 سنوات: | -36.77% (8.05) |
| تغير السعر على مدى 5 سنوات: | +2 470.71% (0.198) |
| تغير الأسعار منذ بداية العام: | +437.49% (0.947) |
|
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
|||||||||||||||||||||||||||||||||||||
| المؤسسات | مقدار | يشارك, % |
|---|---|---|
| Federated Hermes, Inc. | 10154327 | 0 |
| Vivo Capital, LLC | 3242842 | 38.52 |
| Nantahala Capital Management, LLC | 3075414 | 36.53 |
| Stonepine Capital Management, LLC | 2768656 | 32.89 |
| First Manhattan Company | 2680978 | 31.85 |
| Blackstone Inc | 1537684 | 18.27 |
| Vanguard Group Inc | 1407652 | 16.72 |
| Caxton Corporation | 1318967 | 15.67 |
| Sphera Funds Management Ltd. | 996710 | 11.84 |
| Adage Capital Partners GP L.L.C. | 631690 | 7.5 |
| ETF | يشارك, % | الربحية لهذا العام, % | توزيعات الأرباح, % |
|---|---|---|---|
| Avantis U.S Small Cap Equity ETF | 0.01284 | 27.774101036841 | 1.68271 |
| Dimensional U.S. Core Equity 2 ETF | 0.0002 | 30.755198832543 | 1.47098 |
| Dimensional U.S. Targeted Value ETF | 0.00052 | 26.007247921552 | 1.93487 |
| iShares Micro-Cap ETF | 0.05811 | 36.318555985322 | 1.54048 |
| مشرف | مسمى وظيفي | قسط | سنة الميلاد |
|---|---|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, CEO & Acting Chairman of the Board | 973.65k | 1967 (57 سنين) |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 738.86k | 1975 (49 سنين) |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs | N/A | |
| Mr. Michael R. Deperro | Senior VP & Head of Corporate Development | N/A | |
| Mr. Michael Covarrubias | Senior VP & Head of Program & Portfolio Management | N/A | |
| Mr. Chris Milks | VP & Head of Finance | N/A | |
| Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Development | N/A | |
| Ms. Robyn Sweinhart | VP & Head of Quality | N/A | |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial Officer | N/A | 1974 (50 سنين) |
| Ms. Erin O'Boyle | Senior VP & Head of Clinical Operations |
عنوان: United States, Redwood City. CA, 201 Redwood Shores Parkway - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.rezolutebio.com
موقع إلكتروني: https://www.rezolutebio.com
